Endogena Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
111 Pine St Ste 1410, San Francisco, Cal...Phone Number
(415) 433-2262Website
www.endogena.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Endogena Therapeutics
Endogena Therapeutics is a clinical-stage biotech company focused on discovering and developing first-in-class endogenous regenerative medicines aimed at repairing and regenerating tissues and organs. Their innovative approach targets degenerative diseases, particularly in ophthalmology, such as retinitis pigmentosa and age-related macular degeneration, which are prevalent due to aging populations. The company collaborates with leading experts in the field to advance their clinical programs and address high unmet medical needs. By harnessing the potential of adult stem and progenitor cells, Endogena aims to revolutionize treatment paradigms for degenerative conditions.Explore more
Endogena Therapeutics Org Chart
JC
Director of Translational Medicine
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Endogena Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Endogena Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Endogena Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Endogena Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Endogena Therapeutics has new funding data
Click to see if Endogena Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Endogena Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Endogena Therapeutics
Product Launch: Get notified when Endogena Therapeutics launches new products
Recommended Actions
Find VP level buyers at Endogena Therapeutics
Find 2 more new buyers
Compare Similar Companies to Endogena Therapeutics
Compare insights from companies similar to Endogena Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Endogena Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Endogena Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Endogena Therapeutics.
Endogena Therapeutics Tech Stack
A closer look at the technologies used by Endogena Therapeutics
See more technologies
Endogena Therapeutics News & Media
Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration
KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused on the development of endogenous regenerative medicines. Enamine provides Endogena with its integrated capability in medicinal chemistry to support Endogena’s small molecule drug diEndogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive safety and tolEndogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
SAN FRANCISCO, TORONTO and ZÜRICH, Switzerland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the US Food and Drug Administration (FDA) has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development program. Fast Track is a process designed to enable patients to benefit earlier from important new drugs for sEndogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa
ZURICH and TORONTO, July 12, 2022 /PRNewswire/ -- Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Endogena Therapeutics
Sign Up For FreeTo access detailed company insights
Endogena Therapeutics is a clinical-stage biotech company focused on discovering and developing first-in-class endogenous regenerative medicines aimed at repairing and regenerating tissues and organs. Their innovative approach targets degenerative diseases, particularly in ophthalmology, such as retinitis pigmentosa and age-related macular degenera... Read More
